Table I.
HER2 expression in MPBC determined from previous studies.
| Author, year | Patients (n) | Method | IHC positivity, % of stained cells | ISH positivity (HER2/chr17 ratio) | IHC-ISH concordance | Percentage of positive cases | Limitations | Significant association | Independent predictor | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|
| Sangoi et al, 2009 | 24 | IHC | >30a | NA | NA | 25% | NA | NA | NA | (45) |
| Ching et al, 2011 | 19 | IHC+dual-color ISH | >10b | ≥2.2 | 100% | 68% (IHC), 42% (ISH) | NA | NA | NA | (34) |
| Li, 2015 | 16 | IHC+FISH | >10b | ≥2.2 | 100% (3+) | 87.5% (IHC), 25% (FISH) | Limited number of cases | NA | NA | (83) |
| Schneider et al, 2014 | 61 | IHC+FISH | >10 | ≥2.0 | 83% | 49% (IHC), 15% (FISH) | Relatively limited number of cystectomy cases, retrospective and non-randomized study | Cancer-specific survival | Cancer-specific survival | (35) |
| Behzatoğlu et al, 2016 | 60 | IHC | >10c | NA | NA | 56% | NA | NA | NA | (97) |
| Goodman and Osunkoya, 2016 | 27 | IHC | >10 | NA | NA | 74% | Lack of routine performance of FISH | NA | NA | (99) |
a
Uniform intense membrane staining of >30% of cells
b
2+, complete but weak membrane staining in >10% of cells; 3+, intense membrane staining in >30% of cells
c
complete intense circumferential membrane staining. IHC, immunohistochemistry; ISH, in situ hybridization; FISH, fluorescence ISH; chr17, chromosome 17; NA, not applicable/not available.